Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the long-term safety and tolerability of pimavanserin in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease exposed to open-label pimavanserin for up to 52 weeks.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03623321
Study type Interventional
Source ACADIA Pharmaceuticals Inc.
Contact
Status Completed
Phase Phase 3
Start date July 17, 2018
Completion date May 5, 2023

See also
  Status Clinical Trial Phase
Completed NCT03575052 - A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease Phase 3